<DOC>
	<DOC>NCT02801669</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.</brief_summary>
	<brief_title>Study of DU-176b Aged 80 Years or Older</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients with Nonvalvular Atrial Fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy Patients with active bleeding Patients who have poorly controlled hypertension Patients who have liver dysfunction accompanied with disorder of blood coagulation</criteria>
	<gender>All</gender>
	<minimum_age>80 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>anticoagulants</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>prevention</keyword>
	<keyword>atrial fibrillation</keyword>
</DOC>